Breast CancerFDA Approvals, News & Updates

Trodelvy New Therapy Approved for Triple-Negative Breast Cancer

In April, 2020, the FDA approved Trodelvy for the treatment of adults with metastatic triple-negative breast cancer after 2 or more previous therapies.
June 2020 Vol 6 No 3

On April 22, 2020, the FDA approved Trodelvy (sacituzumab govitecan-hziy; from Immunomedics) for the treatment of adults with metastatic (spreading) triple-negative breast cancer, or TNBC, after at least 2 previous therapies.

“Metastatic triple-negative breast cancer is an aggressive form of breast cancer with limited treatment options. Chemotherapy has been the mainstay of treatment for triple-negative breast cancer. The approval of Trodelvy today represents a new targeted therapy for patients living with this aggressive malignancy,” said Richard Pazdur, M.D., Director of the FDA’s Oncology Center of Excellence.

Trodelvy is a Trop-2–directed antibody and topoi­somerase inhibitor drug conjugate, meaning that the drug targets the Trop-2 receptor that promotes the growth and spread of cancer cells, and it is linked to a topoisomerase inhibitor, which kills cancer cells.

About 20% of patients with breast cancers have triple-negative breast cancer, meaning they don’t have any of the 3 biomarkers often seen in breast cancer, including estrogen receptor (or ER), progesterone receptor (or PR), and HER2. Therefore, triple-­negative breast cancer doesn’t respond to hormone therapies that target ER, PR, or HER2.

Among the 108 patients included in the clinical trial that led to the FDA approval of Trodelvy, the tumor was shrinking in response to therapy with Trodelvy in about one-third (33%) of the patients. The average duration of the response was 7.7 months, ranging from 6 months to more than 12 months.

The most common side effects with Trodelvy were nausea, neutropenia (reduced white blood cells), diarrhea, fatigue, anemia, vomiting, hair loss, constipation, decreased appetite, rash, and abdominal pain.

Share this:

Recommended For You
Breast CancerIssue Introductions
The Many Faces and Features of Breast Cancer
By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
Hearing the word “cancer” sets your life in an unexpected (and unwelcomed) direction, but a little education about this disease as you embark on your survivorship can help to make the experience a little less daunting.
Breast CancerInterview with the Advocates
Together, at a Distance
By Kristin Siyahian
Breast cancer survivor Judy Guitelman is uniting the Latina breast cancer survivor community, even during a pandemic.
Breast CancerFDA Approvals, News & Updates
Drug Watch: Recently FDA-Approved Breast Cancer Treatments
There are more treatment options available for breast cancer than ever before – and more are coming. Here’s an overview of the most recently approved medicines.
Breast Cancer
Hormone Receptor–Positive Breast Cancer Explained
By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
ER? PR? HR? We can help you make sense of the “alphabet soup” of a breast cancer diagnosis.
Last modified: June 29, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.